References
1. Mottillo S., Filion K.B., Genest J., et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010; 56 (14): 1113-32. DOI: https://doi.org/10.1016/j.jacc.2010.05.034
2. Stern M., Williams K., Gonzalez-Villalpando C., et al. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care. 2004; 27 (11): 2676-81. DOI: https://doi.org/10.2337/diacare.27.11.2676
3. Hirode G., Wong R.J. Trends in the prevalence of metabolic syndrome in the United States, 2011-2016. JAMA. 2020; 323 (8): 2526-68. DOI: https://doi.org/10.1001/jama.2020.4501
4. Belenkov Y.N., Privalova E.V., Kaplunova V.Y., Zektser V.Y., Vinogradova N.N., Ilgisonis I.S., et al. Metabolic syndrome: development of the issue, main diagnostic criteria. Ratsional’naya farmakoterapiya v kardiologii [Rational Pharmacotherapy in Cardiology]. 2018; 14 (5): 757-64. DOI: https://doi.org/10.20996/1819-6446-2018-14-5-757-764 (in Russian)
5. Belhayara M.I, Mellouk Z., Hamdaoui M.S., et al. The metabolic syndrome: emerging novel insights regarding the relationship between the homeostasis model assessment of insulin resistance and other key predictive markers in young adults of Western Algeria. Nutrients 2020; 12: 727. DOI: https://doi.org/10.3390/nu12030727
6. Zheng Y., Ceglarek U., Huang T., et al. Plasma taurine, diabetes genetic predisposition, and changes of insulin sensitivity in response to weight-loss diets. J Clin Endocrinol Metab. 2016; 101 (10): 3820-6. DOI: https://doi.org/10.1210/jc.2016-1760
7. Agouza I.M.E., Saad A.H., Mahfouz A.A., Hamdy K. Serum taurine level in relation to ophthalmoscopic examination as early marker for diabetic retinopathy. Clin Med Biochem. 2016; 3: e124. DOI: https://doi.org/10.4172/2471-2663.1000124
8. Agouza I.M.E., Taha A., Mahfouz A.A., Shalash N.M., Taha K.H. The possibility of using serum taurine level as an early marker to control complications of diabetic foot. J Diabet Complications Med. 2017; 2: 116. DOI: https://doi.org/10.4172/2475-3211.1000116
9. Maleki V., Mahdavi R., Hajizadeh-Sharafabad F., Alizadeh M. The effects of taurine supplementation on oxidative stress indices and inflammation biomarkers in patients with type 2 diabetes: a randomized, doubleblind, placebo-controlled trial. Diabetol Metab Syndr. 2020; 12: 9. DOI: https://doi.org/10.1186/s13098-020-0518-7
10. Huxtable RJ., Michalk D. Taurine in Health and Disease. Springer Science and Business Media, 2013: 449 p.
11. Schaffer S.W., Jong C.J., Ramila K.C. Azuma J. Physiological roles of taurine in heart and muscle. J Biomed Sci. 2010; 17 (suppl 1): S 2.
12. Schaffer S.W., Azuma J. Mozaffari M. Role of antioxidant activity of taurine in diabetes. Can J Physiol Pharmacol. 2009; 87 (2): 91-9.
13. Kanayama A., Inoue J., Sugita-Konishi Y., Shimizu M., Miyamoto Y. Oxidation of Ikappa Balpha at methionine 45 is one cause of taurine chloramine-induced inhibition of NF-kappa B activation. J Biol Chem. 2002; 77 (27): 24 049-56. DOI: https://doi.org/10.1074/jbc.M110832200
14. Yamori Y., Taguchi T., Mori H., Mori M., et al. Low cardiovascular risks in the middle-aged males and females excreting greater 24-hour urinary taurine and magnesium in 41 WHO-CARDIAC study populations in the world. J Biomed Sci. 2010; 17 (suppl 1): S 21.
15. Wojcik O.P., Koenig K.L., Zeleniuch-Jacquotte A., Pearte C., et al. Serum taurine and risk of coronary heart disease: a prospective, nested case- control study. Eur J Nutr. 2013; 52 (1): 169-78.
16. Murakami S. The physiological and pathophysiological roles of taurine in adipose tissue in relation to obesity. Life Sci. 2017; 86: 80-6.
17. Schuller-Levis G.B., Park E. Taurine and its chloramine: modulators of immunity. Neurochem Res. 2004; 29: 117-26.
18. Kim K.S., Ji H.I., Chung H., et al. Taurine chloramine modulates the expression of adipokines through inhibition of the STAT-3 signaling pathway in differentiated human adipocytes. Amino Acids. 2013; 45: 1415-22.
19. Kim H.M., Do C.H., Lee D.H. Characterization of taurine as anti-obesity agent in C. elegans. J Biomed Sci. 2010; 24 (17 suppl 1): S 33.
20. Zhang M., Bi L.F., Fang J.H., Su X.L., et al. Beneficial effects of taurine on serum lipids in overweight or obese non-diabetic subjects. Amino Acids. 2004; 26 (3): 267-71.
21. Yuzhakova A.E., Nelaeva A.A., Khasanova Y.V. The role of taurine in the correction of disorders of carbohydrate metabolism. Effektivnaya farmakoterapiya [Effective Pharmacotherapy]. 2019; 15 (2): 16-8. DOI: https://doi.org/10.33978/2307-3586-2019-15-22-16-18 (in Russian)
22. Statsenko M.E., Turkina S.V., Gorbacheva E.E., et al. Influence of taurin at the degree of internal obesity and severity of visceral fat dysfunction in patients with non-alcoholic fatty liver disease. Consilium Medicum. 2019; 21 (12): 128-33. DOI: https://doi.org/10.26442/20751753.2019.12.190666 (in Russian)
23. Amato M.C., Giordano C., Pitrone M., Galluzzo A. Cut-off points of the visceral adiposity index (VAI) identifying a visceral adipose dysfunction associated with cardiometabolic risk in a Caucasian Sicilian population. Lipids Health Dis. 2011; 10: 183.
24. Chiang J.Y.L. Regulation of bile acid synthesis. Front Biosci. 1998; 3: 176-93.
25. Vlahcevic Z.R., Pandak W.M., Stravit R.T. Regulation of bile acid biosynthesis. Gastroenterol Clin North Am. 1999; 28: 1-25.
26. Kibe A., Wake C., Kuramoto T., Hoshita T. Effect of dietary taurine on bile acid metabolism in guinea pigs. Lipids. 1980; 15 (4): 224-9.
27. Lam N.V., Chen W., Suruga K., et al. Effects of taurine on mRNA levels of nuclear receptors and factors involved in cholesterol and bile acid homeostasis in mice. Adv Exp Med Biol. 2006; 583: 193-202.
28. Murakami S., Kondo Y., Toda Y., et al. Effect of taurine on cholesterol metabolism in hamsters: up-regulation of low-density lipoprotein (LDL) receptor by taurine. Life Sci. 2002; 70: 2355-66.
29. Yanagita T., Han S.Y., Hu Y., Nagao K., et al. Taurine reduces the secretion of apolipoprotein B 100 and lipids in HepG2 cells. Lipids Health Dis. 2008; 7: 38-43.
30. Nechaeva G.I., Druk I.V., Ryapolova E.A. Efficacy and tolerance of taurine in patients with type 2 diabetes mellitus and left ventricular diastolic dysfunction. Poliklinika [Policlinic]. 2015; (1): 58-62. (in Russian)
31. Statsenko M.E., Shilina N.N., Vinnikova A.A. Possibilities of taurine in the complex therapy of patients with chronic heart failure and type 2 diabetes mellitus. Meditsinskiy alfavit [Medical Alphabet]. 2015; 4 (1): 5-10. (in Russian)
32. Statsenko M.E., Turkina S.V., Shilina N.N. Liver damage in patients with ischemic chronic heart and type 2 diabetes - a treacherous tandem: possible additional organoprotective therapy. Consilium Medicum. 2016; 18 (5): 103-9. (in Russian)
33. Park T., Lee K. Dietary taurine supplementation reduces plasma and liver cholesterol and triglyceride levels in rats fed a high-cholesterol or a cholesterol-free diet. Adv Exp Med Biol. 1998; 442: 319-25.
34. Choi M.J., Kim J.H., Chang K.J. The effect of dietary taurine supplementation on plasma and liver lipid concentrations and free amino acid concentrations in rats fed a high-cholesterol diet. Adv Exp Med Biol. 2006; 583: 235-42.
35. Yu H.R., Zhang N., Dong Y.L., Zhou Q., Zhou Q.X. Effects of taurine on the change of apoptosis induced by IL-1p, TNF-a and IFN-y in rat pancreatic islet cells. Chin J Pathophysiol. 2007; 23 (6): 1172-5.
36. Arany E., Strutt B., Romanus P., et al. Taurine supplement in early life altered islet morphology, decreased insulitis and delayed the onset of diabetes in non-obese diabetic mice. Diabetologia. 2004; 47: 1831-7.
37. El Idrissi A., Boukarrou L., LAmoreaux W. Taurine supplementation and pancreatic remodeling. Adv Exp Med Biol. 2009; 643: 353-8.
38. LAmoreaux W.J., Cuttitta C., Santora A., et al. Taurine regulates insulin release from pancreatic beta cell lines. J Biomed Sci. 2010; 17 (suppl 1): S 11.
39. Carneiro E.M., Latorraca M.Q., Araujo E., et al. Taurine supplementation modulates glucose homeostasis and islet function. J Nutr Biochem. 2009; 20 (7): 503-11.
40. Imae M., Asano T., Murakami S. Potential role of taurine in the prevention of diabetes and metabolic syndrome. Amino Acids. 2014; 46 (1): 81-8.
41. Xiao C., Giacca A., Lewis G.F. Oral taurine but not N-acetylcysteine ameliorates NEFA-induced impairment in insulin sensitivity and beta cell function in obese and overweight, non-diabetic men. Diabetologia. 2008; 51 (1): 139-46.
42. Schaffer S.W., Lombardini J.B., Azuma J. Interaction between the actions of taurine and angiotensin II. Amino Acids. 2000; 18 (4): 305-18.
43. Hano T., Kasano M., Tomari H., Iwane N. Taurine suppresses pressor response through the inhibition of sympathetic nerve activity and the improvement in baro-reflex ensitivity of spontaneously hypertensive rats. Adv Exp Med Biol. 2009; 643: 57-63.
44. Mozaffari M.S., Patel C., Abdelsayed R., Schaffer S.W. Accelerated NaCl-induced hypertension in taurine-deficient rat: role of renal function. Kidney Int. 2006; 70: 329-37. DOI: https://doi.org/10.1038/sj.ki.5001503
45. Fujita T., Ando K., Noda H., Ito Y., Sato Y. Effects of increased adre-nomedullary activity and taurine in young patients with borderline hypertension. Circulation. 1987; 75: 525-32.
46. Yamori Y., Taguchi T., Hamada A., et al. Taurine in health and diseases: consistent evidence from experimental and epidemiological studies. J Biomed Sci. 2010; 17 (suppl): S 6.
47. Katakawa M., Fukuda N., Tsunemi A., et al. Taurine and magnesium supplementation enhances the function of endothelial progenitor cells through antioxidation in healthy men and spontaneously hypertensive rats. Hypertens Res. 2016; 39: 848-56.
48. Sun Q., Wang, B., Li Y., et al. Taurine supplementation lowers blood pressure and improves vascular function in prehypertension: randomized, double-blind, placebo controlled study. Hypertension. 2016; 67: 541-9.